Context: Locally advanced renal cell carcinoma (RCC) is associated with a poor prognosis despite radical surgery. The surgical approach can differ according to tumour size, location, and vascular involvement. The development of molecular targeted therapies aroused new interest in adjuvant and neoadjuvant strategies. Objective: The aim of this article was to review trends in surgical approaches ...

pleuropulmonary blastoma [ppb] is a very rare, highly aggressive and malignant tumor that originates from either the lungs or pleura. it occurs mainly in children aged less than five or six years. it has poor prognosis with three different subtypes: cystic [type i], combined cystic and solid [type ii] and solid [type iii]. ppb is treated with aggressive multimodal therapies including surgery an...

Long-term outcomes for women with a diagnosis of human epidermal growth factor receptor 2 (HER2)-driven early-stage breast cancer have significantly improved since the advent of HER2-targeted therapy. Although the first studies in the early-stage setting focused on the adjuvant use of trastuzumab plus chemotherapy, clinical trials increasingly are using a neoadjuvant design to evaluate novel HE...

Summary Neoadjuvant checkpoint inhibition in resectable non-small-cell lung cancer (NSCLC) is safe and high major pathologic response (MPR) complete (pCR) rates can be achieved combination with chemotherapy. The Checkmate 816 trial gives evidence that also leads to EFS benefit. This opens new opportunities the curative setting but raises questions: What value of adjuvant treatment inhibitors? O...

Since 2005, major progresses have been made in the neoadjuvant treatment of HER2-positive breast cancer. Trastuzumab introduction associated with chemotherapy has been the first major step leading to the improvement of the complete pathological response rate and, like in the adjuvant studies, better survivals. Dual HER2 blockade has been the next step and trastuzumab is associated now with othe...

The traditional drug development process in breast cancer based on large phase III studies has serious limitations and needs a major overhaul. Searching for new approaches, the testing of novel agents in the preoperative (neoadjuvant) setting approach offers a potentially rapid and efficient strategy for drug development utilizing pathologic complete response (path CR), a surrogate marker for s...

Surgical intervention is the mainstay treatment for soft tissue sarcomas (STSs). The significance of adjuvant and neoadjuvant therapies, such as chemotherapy, radiation, and isolated limb perfusion, remains under controversial discussion. The goal of this review is to discuss the effects of the aforementioned treatment modalities and their timing of application in plastic surgery techniques. Fu...

In HER2-positive early breast cancer, neoadjuvant treatment with a combination of sequential chemotherapy and HER2-targeted therapy is currently the standard of care. This is followed by breast surgery, radiotherapy (if indicated), completion of 12 months of HER2-directed therapy, and - depending on the tumor biology - endocrine adjuvant therapy, and ultimately follow up. 10-year survival rates...

SUMMARY: About 10-25% of breast cancer patients achieve a pathologically confirmed complete response after neoadjuvant chemotherapy. Tissue samples of pretreatment core biopsies are a valuable resource for translational research aiming towards predictive biomarkers for selecting patients who are likely to benefit from neoadjuvant therapy. The German Breast Group (GBG) and the AGO-B Group (AGO =...